Cooperative Agreement U01CA294514
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.353
Assistance Type
Cooperative Agreement
Place of Performance
Hamden, CT 06511, USA
Similar Awards
This $1,128,990 Cooperative Agreement award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) will fund the Myeloma Multidimensional Precancer Atlas (MMPCA) project at the Dana-Farber Cancer Institute. The project aims to construct a comprehensive spatial and temporal atlas of precursor stages of multiple myeloma (MM) to understand genomic and microenvironmental alterations across the disease spectrum. Key objectives include: Mapping spatial...
This $1,069,188 Cooperative Agreement award, provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), supports a collaborative research project to construct a comparative spatial atlas of low-grade gliomas. The research team from the University of California, Los Angeles (UCLA) Neurosurgery and the California Institute of Technology (Caltech) Spatial Single Cell team will expand on their preliminary data to generate an...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $1,979,214 to the University of Texas MD Anderson Cancer Center to construct a three-dimensional (3D) ovarian cancer atlas. The atlas will characterize high-grade serous ovarian cancer (HGSOC) metastasis and the development of intrinsic therapeutic resistance using advanced molecular and cellular profiling platforms. The project...
This Project Grant award of $589,591 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports a study to determine barriers leading to inferior survival for Black and Hispanic patients with Hodgkin lymphoma. The key products/services to be delivered include: Examining differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse, particularly for patients who have relapsed....
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $690,772 to New York University School of Medicine to conduct research on mapping and targeting 3D regulatory elements in leukemia and lymphoma. The key objectives are to: A) Extensively map 3D chromatin "hubs" - DNA elements that interact with multiple loci - in primary peripheral T-cell lymphoma (PTCL) specimens. B) Perform CRISPR screens to identify biologically...
The National Cancer Institute (NCI) awarded a $1,032,520 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) program to the Washington University to establish the Human Prostate Tumor Atlas Center (HPTAC). Over the 5-year project period from Sep 1, 2024 to Aug 31, 2029, the HPTAC will develop a molecularly resolved spatial atlas of prostate cancer (PCA) that integrates multi-omics, imaging, and clinical data. The atlas will elucidate PCA...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353), will fund the construction of a three-dimensional (3D) multimodal molecular atlas of colorectal cancer (CRC) across different ages of onset. The $1,063,411 award to Vanderbilt University will support spatial mapping of tumor progression from precancerous to cancerous states, utilizing cutting-edge technologies such as...
The National Cancer Institute (NCI) awarded a $1,019,013 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to the Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The overarching goal is to study the early stages of skin cancer development, including melanoma and cutaneous squamous cell carcinoma, and the role of the immune system in this transition from pre-cancer to cancer. The...
This $2,561,215 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Weill Medical College of Cornell University to investigate the epigenetic and immunological basis of diffuse large B-cell lymphoma (DLBCL). The project aims to: 1) Understand how chromatin and immune signaling pathways regulate key germinal center B-cell fate decisions in DLBCL; 2) Characterize how DLBCL subtypes defined by their chromatin landscapes interact with...
This $178,909 Project Grant awarded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395) aims to accelerate the incorporation of immunotherapy and CD30-targeted cellular therapy into the treatment of Hodgkin lymphoma in children, adolescents, and young adults (AYAs). The award supports the principal investigator, Dr. Castellino, in her role as the Scientific Chair of the Hodgkin Lymphoma Committee in the Children's Oncology Group. Key...